| Name | Nafcillin sodium monohydrate |
| Description | Nafcillin sodium monohydrate (CL 8491) is the sodium salt form of nafcillin, a semi-synthetic naphthalene, penicillin-related Nafcillin inhibits bacterial wall synthesis by a mechanism of action similar to penicillin. Penicillinase-resistant Nafcillin is used to treat infections caused by penicillin-resistant strains of Staphylococci. |
| In vivo | Nafcillin sodium inactivates beta-lactamase by forming a covalent acyl-enzyme intermediate with Ser-70. At concentrations greater than 80 mM, and exposure times less than 200 seconds, Nafcillin completely inhibits the activity of beta-lactamase. Upon removal of Nafcillin, the inhibited enzyme can be fully reactivated with a rate constant of 2×10^-3/s at 25°C. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 16 mg/mL (35.21 mM), Sonication is recommended. H2O : 83 mg/mL (182.63 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (7.26 mM), Sonication is recommended. DMSO : 142.8 mg/mL (314.21 mM), Sonication is recommended.
|
| Keywords | β-Lactamase | staphylococcal | methicillin-susceptible | methicillin-resistant | CL-8491 | CL8491 | bactericidal | Bacterial | Antibiotic |
| Inhibitors Related | Neomycin sulfate | Adipic dihydrazide | Levulinic acid | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Doxycycline | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate | BES |
| Related Compound Libraries | Bioactive Compound Library | Drug-induced Liver Injury (DILI) Compound Library | Toxic Compound Library | Antibiotics Library | Drug Repurposing Compound Library | Beta-Lactam Compound Library | Inhibitor Library | Anti-Bacterial Compound Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library |